$\square$ 

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

2. Issuer Name and Ticker or Trading Symbol Stellar Biotechnologies, Inc. [SBOTF]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
	X Director 10% Owner				
-	Officer (give title Other (specify				
3. Date of Earliest Transaction (Month/Day/Year)	below) below)				
06/10/2015					
4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)				
	X Form filed by One Reporting Person				
	Form filed by More than One Reporting Person				
-	Stellar Biotechnologies, Inc. [SBOTF] - 3. Date of Earliest Transaction (Month/Day/Year) 06/10/2015				

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	Date			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
		Code	v	Amount	(A) or (D)	Price	<ul> <li>Reported Transaction(s) (Instr. 3 and 4)</li> </ul>		(1150.4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Numl of Derivati Securiti Acquire (A) or Dispose of (D) (I 3, 4 and	Expiration Date (Month/Day/Year) ed sstr.		e of Securities ar) Underlying		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$0.72 <sup>(1)</sup>	06/10/2015		A		25,000		(2)	06/10/2022	Common Shares	25,000	\$0	25,000	D	

## **Explanation of Responses:**

1. The options are exercisable at a price of C\$0.89. The U.S. dollar price reported on this Form 4 in column 2 reflects the U.S. dollar equivalent exercise price on the date of grant, calculated at the closing price for cable transfers in Canadian dollars as reported by Bloomberg on such date of U.S. \$1.00=CDN\$1.23

2. One-third of the option vested immediately, one-third of the option vests on the first anniversary of June 10, 2015, and one-third vests 18 months after June 10, 2015.

<u>/s/ Kathi Niffenegger, as</u>	06/12/2015
<u>Attorney in Fact</u>	00/12/2013
** Signature of Reporting Person	Date

Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.